Evidence map›Paper›PMID 30032036›Full record

ArticleNeoplasia (New York, N.Y.)2018

Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.

Amir Farmanbar, Sanaz Firouzi, Wojciech Makałowski, Robert Kneller, Masako Iwanaga, Atae Utsunomiya, Kenta Nakai, Toshiki Watanabe

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Amir FarmanbarDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: amirfarman80@gmail.com.
Sanaz FirouziDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. Electronic address: firouzisanaz1@gmail.com.
Wojciech MakałowskiInstitute of Bioinformatics, Faculty of Medicine, University of Muenster, Germany. Electronic address: wojmak@uni-muenster.de.
Robert KnellerResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. Electronic address: kneller@tt.rcast.u-tokyo.ac.jp.
Masako IwanagaDepartment of Frontier Life Science, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. Electronic address: masakoiwng@nagasaki-u.ac.jp.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan. Electronic address: autsunomiya@jiaikai.jp.
Kenta NakaiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: knakai@ims.u-tokyo.ac.jp.
Toshiki WatanabeDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan; Department of Advanced Medical Innovation St. Marianna University Graduate School of Medicine, Kanagawa, Japan. Electronic address: tnabe@ims.u-tokyo.ac.jp.
The University of Tokyo · JPImamura Hospital · JPNagasaki University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clonal architecture of tumors plays a vital role in their pathogenesis and invasiveness; however, it is not yet clear how this clonality contributes to different malignancies. In this study we sought to address mutational intratumor heterogeneity (ITH) in adult T-cell leukemia/lymphoma (ATL). ATL is a malignancy with an incompletely understood molecular pathogenesis caused by infection with human T-cell leukemia virus type-1 (HTLV-1). To determine the clonal structure through tumor genetic diversity profiles, we investigated 142 whole-exome sequencing data of tumor and matched normal samples from 71 ATL patients. Based on SciClone analysis, the ATL samples showed a wide spectrum of modes over clonal/subclonal frequencies ranging from one to nine clusters. The average number of clusters was six across samples, but the number of clusters differed among different samples. Of these ATL samples, 94% had more than two clusters. Aggressive ATL cases had slightly more clonal clusters than indolent types, indicating the presence of ITH during earlier stages of disease. The known significantly mutated genes in ATL were frequently clustered together and possibly coexisted in the same clone. IRF4, CCR4, TP53, and PLCG1 mutations were almost clustered in subclones with a moderate variant allele frequency (VAF), whereas HLA-B, CARD11, and NOTCH1 mutations were clustered in subclones with lower VAFs. Taken together, these results show that ATL displays a high degree of ITH and a complex subclonal structure. Our findings suggest that clonal/subclonal architecture might be a useful measure for prognostic purposes and personalized assessment of the therapeutic response.

Indexed as

Genetic HeterogeneityGenetic Predisposition to DiseaseMutationBiomarkersComputational BiologyDisease SusceptibilityDNA Copy Number VariationsGenetic VariationGenome-Wide Association StudyHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellPolymorphism, Single NucleotideBiomarkers

Identifiers

PMID30032036
PMCPMC6074008
OpenAlexW2883501308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.